TY - JOUR
T1 - Coordinate expression of Cdc25B and ER-α is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas
AU - Wu, Weiguo
AU - Slomovitz, Brian M.
AU - Celestino, Joseph
AU - Chung, Linda
AU - Thornton, Angela
AU - Lu, Karen H.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/10/1
Y1 - 2003/10/1
N2 - Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-α. We examined the expression of cdc25B and phosphorylated ER-α in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-α was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (χ2 = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-α at high levels, but only 17% (2 of 12) of high-grade EEC did so (χ2 = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-α and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (χ2 = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-α at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (χ2 = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-α and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-α occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-α. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.
AB - Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-α. We examined the expression of cdc25B and phosphorylated ER-α in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-α was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (χ2 = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-α at high levels, but only 17% (2 of 12) of high-grade EEC did so (χ2 = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-α and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (χ2 = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-α at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (χ2 = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-α and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-α occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-α. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=0141919570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141919570&partnerID=8YFLogxK
M3 - Article
C2 - 14559803
AN - SCOPUS:0141919570
SN - 0008-5472
VL - 63
SP - 6195
EP - 6199
JO - Cancer Research
JF - Cancer Research
IS - 19
ER -